Format

Send to

Choose Destination
Eur J Clin Pharmacol. 2017 Feb;73(2):185-195. doi: 10.1007/s00228-016-2156-4. Epub 2016 Nov 17.

Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies.

Author information

1
AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TF, UK.
2
Sandoz, Industriestrasse 25, Holzkirchen, Germany. paul-1.martin@sandoz.com.
3
AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA.
4
Quintiles Inc., 6700 W. 115th St, Overland Park, KS, 66211, USA.
5
LEO Pharma, Industriparken 55, 2750, Ballerup, Denmark.

Abstract

PURPOSE:

Fostamatinib is an orally dosed phosphate prodrug that is cleaved by intestinal alkaline phosphatase to the active metabolite R406. Clinical studies were performed to assess the effect of food and ranitidine on exposure, to support in vitro-in vivo relationships (IVIVR) understanding and formulation transitions and to investigate absolute oral bioavailability.

METHODS:

A series of in vitro dissolution and clinical pharmacokinetic studies were performed to support the design and introduction of a new formulation, understand the impact of changes in in vitro dissolution on in vivo performance for two fostamatinib formulations, to characterize the effects of food and ranitidine on exposure, and determine the absolute oral bioavailability.

RESULTS:

The in vivo performance of fostamatinib was generally insensitive to changes in in vitro dissolution performance, although marked slowing of the dissolution rate did impact exposures. Food and ranitidine had minor effects on R406 exposure that were not considered clinically relevant. The absolute oral bioavailability of fostamatinib was 54.6 %.

CONCLUSIONS:

The absolute oral bioavailability of fostamatinib was ~55 %. Food and ranitidine had minor effects on R406 exposure. An in vitro dissolution versus clinical performance relationship was determined that supported formulation transitions.

KEYWORDS:

Absolute bioavailability; Food effect; Fostamatinib; Pharmacokinetics; Ranitidine DDI; SYK inhibitor

PMID:
27858108
DOI:
10.1007/s00228-016-2156-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center